Morgan Stanley analyst Maxwell Skor assumed coverage of Sana Biotechnology (SANA) with an Overweight rating and $12 price target Six-month data for UP421 in type 1 diabetes show continued cell survival and insulin production without immunosuppression, notes the analyst, who looks forward to an investigational new drug filing for the company’s proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451, as early as next year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology Announces Positive Diabetes Study Results
- Sana reports six-month follow-up results from islet cell transplantation study
- Sana Biotechnology Elects Directors at Annual Meeting
- SANA Lawsuit Alert! Class Action Lawsuit Against Sana Biotechnology, Inc.
- Sana Biotechnology Reports Improved Quarterly Loss